↓ Skip to main content
What is this page? Embed badge

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

Overview of attention for article published in Annals of Oncology, May 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
15 X users
facebook
1 Facebook page
f1000
1 research highlight platform

Readers on

mendeley
49 Mendeley